Alzinova AB
78D
Company Profile
Business description
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is engaged in the development of a specific oligomer-directed vaccine (ALZ-101), and ALZ-201 which is a monoclonal antibody that is specific for the toxic AB oligomers. The products of the company are in the clinical and preclinical stages of development as a therapeutic vaccine for the treatment of Alzheimer’s.
Contact
Entreprenorsstraket 10
Molndal431 53
SWESector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Chart of the Week: AI proving a threat to company moats
The latest insights on AI from our equity research team.
stocks
ASX coal miners will benefit from higher prices
Middle East conflict pushes coal prices higher.
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
We think Nvidia stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,690.70 | 21.10 | -0.24% |
| CAC 40 | 7,853.08 | 116.80 | -1.47% |
| DAX 40 | 23,036.65 | 465.60 | -1.98% |
| Dow JONES (US) | 46,199.62 | 793.64 | -1.69% |
| FTSE 100 | 10,139.01 | 166.28 | -1.61% |
| HKSE | 25,500.58 | 524.84 | -2.02% |
| NASDAQ | 22,152.42 | 327.11 | -1.46% |
| Nikkei 225 | 53,372.53 | 1,866.87 | -3.38% |
| NZX 50 Index | 13,051.61 | 130.62 | -0.99% |
| S&P 500 | 6,626.82 | 89.27 | -1.33% |
| S&P/ASX 200 | 8,497.80 | 7.60 | -0.09% |
| SSE Composite Index | 4,006.55 | 56.43 | -1.39% |